Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
T. Doi
Observed names:
T Doi,
Toshihiko Doi
Institution:
National Cancer Center Hospital East
Observed institution:
National Cancer Center Hospital East
ORCID:
0000-0003-2042-6829
Observed ORCID:
0000-0003-2042-6829
OpenAlex ID:
A5060273183
453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study
2022
·
T. Doi
, M. Patel
, et al.
·
Annals of Oncology
·
46
1007P Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
2024
·
K.J. Harrington
, S. Kitano
, et al.
·
Annals of Oncology
·
4
PDF
917O DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate (ADC), in patients (pts) with advanced/metastatic (adv/met) solid tumors: Initial results from a first-in-human (FIH) study
2025
·
M.R. Patel
, T. Doi
, et al.
·
Annals of Oncology
·
3
Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303)
2026
·
Mao Okada
, Jun Sato
, et al.
·
Japanese Journal of Clinical Oncology
·
2
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers
2021
·
A Diab
, O Hamid
, et al.
·
immuneACCESS
Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)
2018
·
K. Shitara
, J. Tabernero
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
6
Citation count:
55
H-index:
3
I10-index:
1
Year
Topic
Type